in ,


With a philosophy “Pledged To Save Millions”, SMT remains committed to the welfare of all patients worldwide. They continue to advance patient care by introducing state of the art medical equipment to save precious lives globally.


SMT commenced operations in 1998 with a pledge to save millions. The group is the brainchild of the current chairman, Dhirajlal Kotadia. He founded the group with the purpose of catering to the diamond industry with laser technology-based solutions. He eventually diversified the group to becoming the leading manufacturer of minimally invasive coronary stent systems in India, with one of the broadest product portfolio in the industry as manufacturer of herbal medicinal formulations, and biotechnology research. A few years after it commenced operation in Surat, India, the Research and Development team successfully introduced the first indigenously developed coronary stent system in India. Today, the group has created a substantial footprint in the coronary stents market in India. SMT has global presence with its products and facilities available in over 60 countries all over the world. SMT is one of the most recognized stents manufacturers in the world. They have over one million successful implants globally. Their products have been used extensively and proven among the highest number of Indian patients as compared to any other company in the world.


With support and recognition from the Ministry of Science and Technology, Government of India, the Research and Development facility of Sahajanand Medical Technologies has, through its highly qualified research personnel, continuously improved stent designs. These new designs and breakthroughs have helped physicians in placing stents in more challenging anatomies and at the same time, retain the efficiency and safety of the previous generations. SMT now has its 4th generation design in the market. This new design has seen tremendous demand in the Indian markets.

Sahajanand Medical Technologies was the first company in the world to receive a CE approval for their biodegradable polymer-based drug eluting stents (DES). It also scored another first when it introduced a blend of biodegradable polymer matrix. This type of polymer matrix has become the most preferred polymer and has been proven to be the safest. It is very durable and thin (just 4 to 6 microns thick) thanks to the unique blending of biodegradable polymers. The unique blend also helps it achieve a precise drug release, which ensures the safety and efficacy of the PCI (Percutaneous Coronary Intervention) procedure for the patient.

SMT has also become the first company to offer up to eight coronary stents, thus providing the cardiologist with options to choose from. Some of these products are: Tetriflex, Tetrilimus, Supraflex, Evroflex, Supralimus Cruz, etc. It is also the first Indian company to have 2 Randomized Controlled Trials namely ‘Paint’ and ‘Talent’ trials. ‘Talent’ is an ongoing Randomized Controlled Trial covering over 1,400 patients, being conducted at 27 centers spread out over 7 countries in Europe. Sahajanand Medical Technologies stents have been tested on various parameters such as Radial Strength, Conformability, and Recoil and they performed excellently.

SMT (Sahajanand Medical Technologies) is the leading manufacturer of minimally invasive coronary stent systems in India. They have one of the broadest product portfolios in the industry. Some of the products in their portfolio are drug eluting stents (DES), bare metal stents, inflation devices, and balloon catheters. Their high-quality products are accepted in over 60 countries. They aim to expand their portfolio to comprehensively cover all aspects of cardiovascular treatment support.


Sahajanand Medical Technologies has received a lot of prestigious awards since its inception. In 2017, it was recognized as one of the ‘Iconic Brands of India’ by Economic Times. It was also recognized as the ‘Best Healthcare Brand: 2016’.

One of the more outstanding awards is the 6th National Award for the category “Polymers in Public Health Care” which SMT received for “The use of biodegradable polymers for controlled drug delivery form cardiovascular stents”. The Award was given by the Honorable Minister for Chemicals and Fertilizers, Govt. of India – Shri Ananth Kumar – on January 20, 2016. It has also won National Awards for excellence in health care in the categories “The best R&D in medical devices” and “The best quality in medical devices”. 

Other awards received by the SMT group include:

  • India Medical Devices Company of the Year award, hosted by Frost and Sullivan Alexandria in 2011
  • Pride of India Leadership Award to the Chairman of the SMT group – Mr Dhirajtal Kotadia in 2011
  • Award for outstanding work in Research and Development from Southern Gujarat Chamber of Commerce Industry (SGCCI) in 2005-2006
  • Ram Krishna Bajaj National Quality Award from Indian Merchants’ Chamber in 2006.
  • Award for outstanding performance in Chemicals and Pharmaceuticals from SGCCI in 2005-06

SMT is major contributor in the life sciences sector through their continuous innovations. They continue to set industry standards and provide products that save lives. SMT has always believed in “Evidence Based Medicine”. It has over the data of over 12,000 patients published in reputed indexed journals such as the British Medical Journal, Journal of the American College of Cardiology, Journal of Chemical Thermodynamics (UK), Minerva Cardio (Italy), among others. SMT products and facilities have been audited by various reputed agencies and have been approved for sale in over 60 countries. It is no wonder then, that the Sahajanand Medical Technologies group is recognized worldwide as a leader in the coronary stents manufacturing field.

Written by denesof

J. C. Chaudhry